Aerospace & Defense - Fasteners and Assembly Components
Strategic Profile
LISI has achieved organic growth exceeding 10% for the fourth consecutive year, with consolidated revenue reaching a record €1,747.9 million in 2025. The company was included in the SBF 120 and CAC Mid 60 indices in December 2025, marking a strategic milestone reflecting market confidence in its vision.
Cyborg Score Rationale
LISI demonstrates robust operational momentum with consecutive years of double-digit organic growth, record revenue, and significant profitability metrics (€50M+ free cash flow). The aerospace exposure provides exposure to secular growth trends, though recent medical division divestiture and automotive restructuring signal strategic repositioning toward higher-margin segments.
Top Insights
Fourth consecutive year of organic growth exceeding 10%, with 2025 consolidated revenue at record €1,747.9M (+11.5% at constant exchange rates and scope)
Improved earnings per share (BNA doubled) and EBITDA growth with free cash flow remaining positive at €50M+
Divested 100% of LISI MEDICAL division to SK CAPITAL for €270.4M net, with 9.988% minority reinvestment to focus on higher-margin aerospace and automotive
Announced industrial reorganization of automotive operations including Puiseux-Pontoise site shutdown and integration of Hungarian acquisition
Named Competitors
Aerospace Fasteners and Components — Structural fasteners, installation tools, and motor mounts for commercial and defense aircraft
Automotive Assembly Components — Motor mounts, fasteners, and safety components for automotive manufacturers
Medical Implant Manufacturing — Subcontractor manufacturing of medical and ancillary implants
Recent Developments
(January 2026) LISI AUTOMOTIVE announced manufacturing reorganization with Puiseux-Pontoise site closure and production transfers
(December 2025) LISI Group included in SBF 120 and CAC Mid 60 indices following Euronext quarterly review
(October 2025) Sold 100% of LISI MEDICAL division to SK CAPITAL for €270.4M net with minority stake reinvestment
(Full Year 2025) Record revenue of €1,747.9M with 11.5% organic growth at constant scope
Open the full interactive LISI S.A. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.